NeuroMetrix, Inc. (NURO) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NeuroMetrix, Inc. (NURO) Bundle
Streamline your analysis and improve precision with our (NURO) DCF Calculator! Utilizing real NeuroMetrix data and customizable assumptions, this tool empowers you to forecast, analyze, and value NeuroMetrix, Inc. like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.3 | 7.4 | 8.3 | 8.3 | 5.9 | 5.4 | 4.9 | 4.4 | 4.0 | 3.6 |
Revenue Growth, % | 0 | -20.43 | 11.87 | 0.03125949 | -28.52 | -9.26 | -9.26 | -9.26 | -9.26 | -9.26 |
EBITDA | -8.8 | -2.0 | -2.2 | -4.7 | -7.1 | -3.3 | -3.0 | -2.7 | -2.4 | -2.2 |
EBITDA, % | -94.8 | -27.17 | -26.76 | -56.84 | -120.24 | -61.11 | -61.11 | -61.11 | -61.11 | -61.11 |
Depreciation | .1 | .1 | .1 | .0 | .1 | .1 | .0 | .0 | .0 | .0 |
Depreciation, % | 1.34 | 1.22 | 0.9254 | 0.59824 | 0.94404 | 1 | 1 | 1 | 1 | 1 |
EBIT | -8.9 | -2.1 | -2.3 | -4.7 | -7.2 | -3.3 | -3.0 | -2.7 | -2.5 | -2.2 |
EBIT, % | -96.13 | -28.39 | -27.68 | -57.43 | -121.18 | -61.93 | -61.93 | -61.93 | -61.93 | -61.93 |
Total Cash | 3.1 | 5.2 | 22.6 | 21.2 | 18.0 | 4.3 | 3.9 | 3.6 | 3.2 | 2.9 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .5 | .3 | .3 | .6 | .5 | .3 | .3 | .3 | .2 | .2 |
Account Receivables, % | 5.26 | 4.53 | 3.77 | 7.83 | 8.79 | 6.04 | 6.04 | 6.04 | 6.04 | 6.04 |
Inventories | 1.2 | 1.1 | .7 | 1.6 | 1.6 | .9 | .8 | .7 | .7 | .6 |
Inventories, % | 12.55 | 14.25 | 8.56 | 19.56 | 26.42 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
Accounts Payable | .7 | .1 | .3 | .4 | .2 | .2 | .2 | .2 | .2 | .2 |
Accounts Payable, % | 7.83 | 1.93 | 3.44 | 4.46 | 3.65 | 4.26 | 4.26 | 4.26 | 4.26 | 4.26 |
Capital Expenditure | .0 | .0 | -.1 | .0 | -.2 | -.1 | -.1 | .0 | .0 | .0 |
Capital Expenditure, % | -0.51848 | 0 | -1.6 | -0.28079 | -3.11 | -1.1 | -1.1 | -1.1 | -1.1 | -1.1 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -8.6 | -2.0 | -2.2 | -4.7 | -7.2 | -3.2 | -2.9 | -2.7 | -2.4 | -2.2 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -9.5 | -2.2 | -1.8 | -5.8 | -7.2 | -2.3 | -2.9 | -2.6 | -2.3 | -2.1 |
WACC, % | 14.7 | 14.7 | 14.7 | 14.71 | 14.71 | 14.7 | 14.7 | 14.7 | 14.7 | 14.7 |
PV UFCF | ||||||||||
SUM PV UFCF | -8.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -2 | |||||||||
Terminal Value | -17 | |||||||||
Present Terminal Value | -9 | |||||||||
Enterprise Value | -17 | |||||||||
Net Debt | -1 | |||||||||
Equity Value | -15 | |||||||||
Diluted Shares Outstanding, MM | 1 | |||||||||
Equity Value Per Share | -14.86 |
What You Will Get
- Real NeuroMetrix Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on NeuroMetrix’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive NURO Data: Pre-filled with NeuroMetrix’s historical performance metrics and future growth projections.
- Customizable Parameters: Modify revenue forecasts, profit margins, discount rates, tax implications, and capital investment assumptions.
- Interactive Valuation Framework: Automatic recalculation of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive User Interface: Designed to be straightforward and accessible for both industry experts and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered NeuroMetrix data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for NeuroMetrix’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for NeuroMetrix, Inc. (NURO)?
- Accurate Data: Up-to-date NeuroMetrix financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from square one.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare technology sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Investors: Accurately evaluate NeuroMetrix, Inc.'s (NURO) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to NeuroMetrix, Inc. (NURO).
- Consultants: Quickly customize the template for valuation reports tailored to NeuroMetrix, Inc. (NURO) clients.
- Entrepreneurs: Gain insights into financial modeling practices employed by leading companies like NeuroMetrix, Inc. (NURO).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to NeuroMetrix, Inc. (NURO).
What the Template Contains
- Historical Data: Includes NeuroMetrix, Inc.'s (NURO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate NeuroMetrix, Inc.'s (NURO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of NeuroMetrix, Inc.'s (NURO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.